{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of October 2023): No"],"condition":["Pancreatic cancer","Colorectal cancer","Advanced Solid Tumor","Neoplasms"],"disease":["Colorectal Cancer","Advanced Solid Tumor","Pancreatic Cancer","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/114258"],"location":["China"],"study_start_month":["11"],"keyword":["NKG2A","Urothelial carcinoma","Humanized monoclonal antibody"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study of HY-0102 in Patients With Advanced Solid Tumors","description":"This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.","dates":{"creation":"2023-11-15"},"accession":"114258","cross_references":{"ClinicalTrials___gov":["NCT06094777"]}}